Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2019

Open Access 01-10-2019 | Melanoma | Focussed Research Review

Unlocking the therapeutic potential of primary tumor-draining lymph nodes

Authors: Jossie Rotman, Bas D. Koster, Ekaterina S. Jordanova, A. Marijne Heeren, Tanja D. de Gruijl

Published in: Cancer Immunology, Immunotherapy | Issue 10/2019

Login to get access

Abstract

Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.
Literature
1.
2.
Farnsworth RH, Achen MG, Stacker SA (2018) The evolving role of lymphatics in cancer metastasis. Curr Opin Immunol 53:64–73PubMed
3.
Zaal A, Zweemer RP, Zikán M, Dusek L, Querleu D, Lécuru F et al (2014) Pelvic lymphadenectomy improves survival in patients with cervical cancer with low-volume disease in the sentinel node: a retrospective multicenter cohort study. Int J Gynecol Cancer 24:303–311PubMed
4.
Kenter GG, Hellebrekers BWJ, Zwinderman KH, De Vijver M, Van Peters LAW, Trimbos JB (2000) The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma. Acta Obs Gynecol Scand 79:72–76
5.
Shah M, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ et al (2011) Therapeutic role of lymphadenectomy for cervical cancer. Cancer 117:310–317PubMed
6.
D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529PubMed
7.
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211–2222PubMedPubMedCentral
8.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918–926PubMedPubMedCentral
9.
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1–10PubMed
10.
Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJP et al (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 187:1157–1165PubMed
11.
Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren G (2002) Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 33:1193–1199PubMed
12.
Kim MH, Seo SS, Song YS, Kang DH, Park IA, Kang SB et al (2003) Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol Oncol 90:83–90PubMed
13.
Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M et al (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786–1790PubMed
14.
van de Ven R, Lindenberg JJ, Oosterhoff D, de Gruijl TD (2013) Dendritic Cell plasticity in tumor-conditioned skin: CD14(+) cells at the cross-roads of immune activation and suppression. Front Immunol. 4:403PubMedPubMedCentral
15.
Swartz MA, Lund AW (2012) Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 12:210–219PubMed
16.
Chen J, Wang L, Yao Q, Ling R, Li K, Wang H (2004) Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res 6:R474–R477PubMedPubMedCentral
17.
Elliott B, Cook MG, John RJ, Powell BWEM, Pandha H, Dalgleish AG (2004) Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods 291:71–78PubMed
18.
Vuylsteke RJCLM, van Leeuwen PAM, Meijer S, Wijnands PGJTB, Statius Muller MG, Busch DH et al (2002) Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 161:19–26PubMedPubMedCentral
19.
Heeren AM, van Dijk I, Berry DRAI, Khelil M, Ferns D, Kole J et al (2018) Indoleamine 2,3-dioxygenase expression pattern in the tumor microenvironment predicts clinical outcome in early stage cervical cancer. Front Immunol 9:1598PubMedPubMedCentral
20.
Ferns DM, Heeren AM, Samuels S, Bleeker MCG, de Gruijl TD, Kenter GG et al (2016) Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J Immunother Cancer 4:78PubMedPubMedCentral
21.
Heeren AM, de Boer E, Bleeker MCG, Musters RJP, Buist MR, Kenter GG et al (2015) Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget 6:32484–32493PubMedPubMedCentral
22.
Cochran AJ, Morton DL, Stern S, Lana AMA, Essner R, Wen D-R (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14:604–608PubMed
23.
Cochran AJ, Huang RR, Lee J, Itakura E, Leong SPL, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670PubMed
24.
Van De Ven R, Van Den Hout MFCM, Lindenberg JJ, Sluijter BJR, Van Leeuwen PAM, Lougheed SM et al (2011) Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood 118:2502–2510PubMed
25.
Segura E, Valladeau-Guilemond J, Donnadieu M-H, Sastre-Garau X, Soumelis V, Amigorena S (2012) Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 209:653–660PubMedPubMedCentral
26.
Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R et al (2015) Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol Res 3:495–505PubMed
27.
van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM et al (2017) Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunol Res 5:969–977PubMed
28.
Vollmer J, Krieg AM (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61:195–204PubMed
29.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472–492PubMedPubMedCentral
30.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845–1855PubMedPubMedCentral
31.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789–1801PubMed
32.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823PubMed
33.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824–1835PubMed
34.
Vuylsteke RJCLM, Molenkamp BG, Gietema HA, Van Leeuwen PAM, Wijnands PGJTB, Vos W et al (2004) Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 64:8456–8460PubMed
35.
Molenkamp BG, Van Leeuwen PAM, Meijer S, Sluijter BJR, Wijnands PGJTB, Baars A et al (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13:2961–2969PubMed
36.
Molenkamp BG, Sluijter BJR, Van Leeuwen PAM, Santegoets SJAM, Meijer S, Wijnands PGJTB et al (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532–4542PubMed
37.
Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A et al (2017) Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I-II melanoma: data from two randomized phase II trials. Clin Cancer Res 23:5679–5686PubMed
38.
Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E et al (2014) Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 25:1128–1136PubMedPubMedCentral
39.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF et al (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54–67PubMedPubMedCentral
40.
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72PubMed
41.
Honkoop AH, Luykx-de Bakker SA, Hoekman K, Meyer S, Meyer OW, van Groeningen CJ et al (1999) Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 4:106–111PubMed
42.
Pinedo H, Buter J, Luykx-de Bakker S, Pohlmann P, van Hensbergen Y, Heideman DA et al (2003) Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39:1061–1067PubMed
43.
De Vos Van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, Van Der Hulst JM, Goedemans R et al (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70:2707–2717PubMed
44.
Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B et al (2017) Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356:200–205PubMedPubMedCentral
45.
Biewenga P, van der Velden J, Mol BWJ, Stalpers LJA, Schilthuis MS, van der Steeg JW et al (2011) Prognostic model for survival in patients with early stage cervical cancer. Cancer 117:768–776PubMed
46.
Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG et al (2015) High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer. Cancer Immunol Res 3:48–58PubMed
47.
Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A (2006) The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 208:507–517PubMed
48.
Heeren AM, Kenter GG, Jordanova ES, de Gruijl TD (2015) CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: a new therapeutic lead? Oncoimmunology 4:e1009296PubMedPubMedCentral
49.
Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam AGM et al (2013) IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PLoS One 8:e70237PubMedPubMedCentral
50.
(2018) Pembrolizumab OK’d for cervical cancer. Cancer Discov 8:904
51.
Rotman J, Mom CH, Jordanova ES, de Gruijl TD, Kenter GG (2018) ‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) intratumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. BMC Cancer 18:888PubMedPubMedCentral
52.
Marabelle A, Tselikas L, de Baere T, Houot R (2017) Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol 28:xii33–xii43PubMed
53.
Koster BD, de Gruijl TD, van den Eertwegh AJM (2015) Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Curr Opin Oncol 27:482–488PubMed
54.
55.
Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJM (2013) Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19:5381–5389PubMed
56.
Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S et al (2017) Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci 114:E761–E770PubMedPubMedCentral
57.
Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M et al (2018) Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight 3:e124507PubMedCentral
58.
McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469PubMedPubMedCentral
Metadata
Title
Unlocking the therapeutic potential of primary tumor-draining lymph nodes
Authors
Jossie Rotman
Bas D. Koster
Ekaterina S. Jordanova
A. Marijne Heeren
Tanja D. de Gruijl
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02330-y

Other articles of this Issue 10/2019

Cancer Immunology, Immunotherapy 10/2019 Go to the issue

Original Article

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Original Article

Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells

Original Article

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients

Focussed Research Review

Natural killer cells control metastasis via structural editing of primary tumors in mice

Original Article

Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment

Original Article

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits